Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma

Cancer Science

Volumn 100, Issue 8, 2009, Pages 1403-1407

  Shirakawa, Hirofumi ^a,c   Suzuki, Hitomi ^a   Shimomura, Manami ^a   Kojima, Motohiro ^b   Gotohda, Naoto ^c   Takahashi, Shinichiro ^c   Nakagohri, Toshio ^c   Konishi, Masaru ^c   Kobayashi, Nobuaki ^d   Kinoshita, Taira ^c   Nakatsura, Tetsuya ^a  

^a Investigative Treatment Division   (Japan)

^b National Cancer Center   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYPICAN 3;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TUMOR DIFFERENTIATION;

AGED; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; GLYPICANS; HEPATECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 67650648501     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01206.x     Document Type: Article

References (25)

1. Thomas MB, Zhu AX. Hepatocellular carcinoma: The need for progress. J Clin Oncol 2005; 23: 2892-9.
2. Ibrahim S, Roychowdhury A, Hean TK. Risk factors for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. Am J Surg 2007; 194: 17-22.
3. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: A systematic review. Eur J Cancer 2007; 43: 979-92.
4. Filmus J. The contribution of in.vivo manipulation of gene expression to the understanding of the function of glypicans. Glycoconj J 2002; 19: 319-23.
5. Filmus J, Capurro M, Rast J. Glypicans. Genome Biol 2008; 9: 224.
6. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005; 65: 6245-54.
7. Song HH, Shi W, Xiang YY, Filmus J. The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem 2005; 280: 2116-25.
8. Stigliano I, Puricelli L, Filmus J, Sogayar MC, Bal de Kier Joffe E, Peters MG. Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation. Breast Cancer Res Treat 2009; 114: 251-62.
9. Torisu Y, Watanabe A, Nonaka A et al. Human homolog of NOTUM, overexpressed in hepatocellular carcinoma, is regulated transcriptionally by beta-catenin/TCF. Cancer Sci 2008; 99: 1139-46.
10. Hippo Y, Watanabe K, Watanabe A et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004; 64: 2418-23.
11. Capurro M, Wanless IR, Sherman M et al. Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125: 89-97.
12. Nakatsura T, Yoshitake Y, Senju S et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306: 16-25.
13. Nakatsura T, Nishimura Y. Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. Biodrugs 2005; 19: 71-7.
14. Ikuta Y, Nakatsura T, Kageshita T et al. Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clin Cancer Res 2005; 11: 8079-88.
15. Nakatsura T, Kageshita T, Ito S et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004; 10: 6612-21.
16. Wang XY, Degos F, Dubois S et al. Glypican-3 expression in hepatocellular tumors: Diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006; 37: 1435-41.
17. Libbrecht L, Severi T, Cassiman D et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006; 30: 1405-11.
18. Di Tommaso L, Franchi G, Park YN et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007; 45: 725-34.
19. Yamauchi N, Watanabe A, Hishinuma M et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005; 18: 1591-8.
20. Yamamoto J, Kosuge T, Takayama T et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 1996; 83: 1219-22.
21. Portolani N, Coniglio A, Ghidoni S et al. Early and late recurrence after liver resection for hepatocellular carcinoma: Prognostic and therapeutic implications. Ann Surg 2006; 243: 229-35.
22. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89: 500-7.
23. Sakon M, Umeshita K, Nagano H et al. Clinical significance of hepatic resection in hepatocellular carcinoma: Analysis by disease-free survival curves. Arch Surg 2000; 135: 1456-9.
24. Motomura Y, Ikuta Y, Kuronuma T et al. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: Preclinical study using mice. Int J Oncol 2008; 32: 985-90.
25. Komori H, Nakatsura T, Senju S et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006; 12: 2689-97.